Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02259309 · ClinicalTrials.gov registry record · Early Phase 1
Immune Modulation by Misoprostol
A Early Phase 1 study of Gynecological Infection, sponsored by Vanderbilt University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02259309 is a Early Phase 1 study of Gynecological Infection that has completed, run by Vanderbilt University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02259309, a Early Phase 1 study of Gynecological Infection, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.
Conditions Studied
Interventions
- DRUG Misoprostol - buccal
- DRUG Misoprostol - vaginal
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02259309
The ClinicalTrials.gov registry entry for NCT02259309 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gynecological Infection appearing as the primary indexed condition, and to 2 interventions - of which Misoprostol - buccal is the first listed.
NCT02259309 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT02259309 about?
NCT02259309 is a clinical study titled "Immune Modulation by Misoprostol". The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.
What is the current status of trial NCT02259309?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2014-11. Estimated completion is 2015-11.
What conditions does trial NCT02259309 study?
This clinical trial studies the following conditions: Gynecological Infection.
What interventions are being tested in trial NCT02259309?
The interventions under investigation include: Misoprostol - buccal (DRUG), Misoprostol - vaginal (DRUG).
Who is sponsoring clinical trial NCT02259309?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02259309 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.